R (on the application of Blue Bio Pharmaceuticals Ltd and another) v Secretary of State for Health (acting by executive agency MHRA)

European Union – Freedom of movement. The claimant companies issued judicial review proceedings, challenging the defendant Secretary of State's refusal to treat as medicinal products the large number of glucosamine-containing products (GCP) described as food supplements. The Administrative Court, in dismissing the application, held that the claimants had failed to establish that the defendant had erred in refusing to treat all GCPs, alternatively, all GCPs marketed with a daily recommended dose of 1500mg, as medicinal products.

Category: